CY-MET-RICNCT06252870
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
At risk: Primary completion moved 2 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Oct 18, 2027 to Oct 18, 2029
- Eligibility criteria expanded, about 29 words
- Study completion pushed from Jul 18, 2028 to Jul 18, 2030
- Secondary endpoints: details revised at 3 of 13 entries
- Minor Site details revised at 1 of 3 sitesv4
Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
- Study sites: 0 to 3
- Primary completion date: Sep 15, 2027 to Oct 18, 2027
- Study completion date: May 15, 2028 to Jul 18, 2028
- Start date changed from estimate of May 15, 2024 to Jul 18, 2024
- Notable Eligibility criteria expanded, about 50 words
- Primary endpoint revised
- Enrollment target: 60 to 82
- Secondary endpoints: 12 to 13
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of grade 3-4 acute GVHD following allo-CSH for all patients and for each conditioning group (Baltimore and TBF).
Timeframe: Post-transplant through study completion, an average of 1 year
Secondary (13)
Incidence of engraftment
Overall survival (OS)
Disease-free survival (DFS)
GVHD and relapse-free survival (GRFS)
Incidence of acute GVHD grade 2-4
Show 8 moreShow less
Incidence of chronic GVHD
Incidence of corticoresistant acute GVHD
Incidence of non-relapse mortality (NRM)
Incidence of relapse
Chimerism
Immune reconstitution
Grade 3 and 4 post-transplant adverse events
Incidence of viral, bacteriological, fungal and parasitic infections
Arms and interventions
(CLO)-BALTIMOREExperimental
BALTIMORE conditioning regime for LYMPHOID HEMOPATHY CLO-BALTIMORE conditioning regime for MYELOID HEMOPATHY
TBFActive comparator
Conditioning regimen for LYMPHOID AND MYELOID HEMOPATHY
Drugs: Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine, Cycophosphamide, Anti-Thymoglobulin, Clofarabine, Thiotepa, Busulfan
Radiation: total body irradiation
Other: hematopoietic stem cells, Graft nuclear cells, Donor Lymphocytes Injection
Sites
3 sites in 1 country